KATARZYNA SMITH: Open Payments
NPI 1750800215 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$935 in 46 payments from 17 companies in 2025. Trend: 2023 $142 · 2024 $0 · 2025 $935
Food & beverage: $935
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $217 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $108 |
| Amgen Inc. | 5 | $105 |
| Dexcom, Inc. | 3 | $80 |
| ABBVIE INC. | 4 | $80 |
| Mannkind Corporation | 3 | $66 |
| Radius Health, Inc. | 3 | $52 |
| Tandem Diabetes Care, Inc. | 1 | $35 |
| Chiesi USA, Inc. | 1 | $28 |
| Corcept Therapeutics | 1 | $25 |
Products named: Ozempic, Kerendia, Dexcom G6 Transmitter, Wegovy, AFREZZA, TEPEZZA, Tymlos, REPATHA.
Industry payments across MD — which companies pay providers there.
